Markus Jensen
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Immune Cell Function and Interaction 3
- Immunotherapy and Immune Responses 3
- T-cell and B-cell Immunology 2
-
- Monoclonal and Polyclonal Antibodies Research 5
- Co-authors
- Michael Hallek (2 shared papers)Heinz Mehlhorn (1 shared paper)Frank Berthold (5 shared papers)Joachim L. Schultze (3 shared papers)Alexey Popov (1 shared paper)Percy A. Knolle (1 shared paper)Michael von Bergwelt‐Baildon (1 shared paper)Svenja Debey (1 shared paper)
- Journals
- Journal of Immunotherapy (3 papers)Journal of Clinical Oncology (3 papers)Immunology Letters (1 paper)CPT Pharmacometrics & Systems Pharmacology (1 paper)Circulation (1 paper)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Markus Jensen
17 papers receiving 1.3k citations
Markus Jensen's Hit Papers
Peers
Comparison fields: 5 of 91
- Hepatology 336
- Genetics 326
- Immunology 468
- Pathology and Forensic Medicine 335
- Oncology 289
Countries citing papers authored by Markus Jensen
This map shows the geographic impact of Markus Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Jensen more than expected).
Fields of papers citing papers by Markus Jensen
This network shows the impact of papers produced by Markus Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Jensen. The network helps show where Markus Jensen may publish in the future.
Co-authors
The 25 scholars most cited alongside Markus Jensen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2014 | 451 |
| 2 | 2005 | 417 | |
| 3 | 2005 | 159 | |
| 4 | 2009 | 86 | |
| 5 | 2007 | 76 | |
| 6 | 1996 | 68 | |
| 7 | 2021 | 36 | |
| 8 | 2007 | 24 | |
| 9 | 2016 | 19 | |
| 10 | 1997 | 16 | |
| 11 | 2009 | 9 | |
| 12 | 2004 | 6 | |
| 13 | 2007 | 5 | |
| 14 | 2006 | 5 | |
| 15 | 2025 | 2 | |
| 16 | Abstract 15196: A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study | 2017 | 1 |
| 17 | 2013 | 1 |
About Markus Jensen
Markus Jensen is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology and Genetics, having authored 17 papers that have together received 1.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (5 papers), Immune Cell Function and Interaction (3 papers), CAR-T cell therapy research (3 papers), Immunotherapy and Immune Responses (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Glycosylation and Glycoproteins Research (2 papers), T-cell and B-cell Immunology (2 papers) and Neuroblastoma Research and Treatments (2 papers). The work is most often cited by research in Hepatology (336 citations), Genetics (326 citations), Immunology (468 citations), Pathology and Forensic Medicine (335 citations) and Oncology (289 citations). Markus Jensen has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Michael Hallek, Heinz Mehlhorn, Frank Berthold, Joachim L. Schultze, Alexey Popov, Percy A. Knolle, Michael von Bergwelt‐Baildon, Svenja Debey, Kamruz Darabi and Elmar Endl. Their work appears in journals such as Journal of Immunotherapy, Journal of Clinical Oncology, Immunology Letters, CPT Pharmacometrics & Systems Pharmacology and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.